Stocks · News reference
Inogen (NASDAQ:INGN) lowers FY2026 sales outlook from $366.000 million-$373.000 million to $355.000 million-$361.000 million vs $369.267 million estimate.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Inogen, Inc. announced its third-quarter 2026 financial results, the appointment of Andy Reding as CEO, and the sale of its U.S. oxygen rental business as part of a strategic restructuring.
Inogen reported Q3 2026 results showing mixed performance with U.S. sales growth of 3.8% driven by new products, but international sales declined 9% due to European customer softness. The company divested its U.S. oxygen rental business for $24.8 million and announced a $20 million cost-reduction program to accelerate profitability. New CEO Andrew Reding outlined plans to streamline operations and expand into adjacent respiratory markets with Aurora and Voxi products. Full-year revenue guidance is $298-301 million with adjusted net loss of $7-8 million.
Inogen (NASDAQ:INGN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Filed: 2026-09-30 AccNo: 0001294133-26-000037 Size: 195 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
The health care sector's oversold stocks present buying opportunities for undervalued companies. RSI compares stock strength on up and down days, with an RSI below 30 considered oversold.